VNDA Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1347178 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.1%
TTM net income YoY-226.4%
TTM EPS YoY-220.8%
Revenue 3-yr CAGR2.7%
Net income 3-yr CAGR—
Margins
Gross margin93.6%
Operating margin-77.6%
Net margin-119.9%
FCF margin-61.0%
EBITDA margin-77.1%
Returns
ROE-82.5%
ROA-55.9%
ROIC (approx.)-52.6%
Asset turnover0.47x
Leverage & solvency
Liabilities / assets47.7%
Debt / equity0.00x
Current ratio1.54x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.51x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $216.10M | $198.77M |
| Cost of revenue | $13.04M | $11.31M |
| Gross profit | $203.06M | $187.46M |
| R&D expense | $109.27M | $74.43M |
| SG&A expense | $237.95M | $146.41M |
| Operating income | -$151.17M | -$40.66M |
| Pretax income | -$138.65M | -$22.92M |
| Income tax | $81.83M | -$4.02M |
| Net income | -$220.47M | -$18.90M |
| EBITDA | -$150.06M | -$39.80M |
| EPS (basic) | -3.74 | -0.33 |
| EPS (diluted) | -3.74 | -0.33 |
| Weighted avg. shares (diluted) | 58.93M | 58.15M |
| Balance sheet | ||
| Cash & equivalents | $84.85M | $102.78M |
| Receivables | $54.58M | $47.10M |
| Inventory | $1.85M | $1.73M |
| Current assets | $347.26M | $438.89M |
| PP&E, net | $2.25M | $2.13M |
| Intangibles | $117.09M | $114.10M |
| Total assets | $488.95M | $656.20M |
| Current liabilities | $145.16M | $99.98M |
| Total liabilities | $161.76M | $117.66M |
| Shareholders' equity | $327.19M | $538.55M |
| Shares outstanding | 59.10M | 58.31M |
| Cash flow statement | ||
| Operating cash flow | -$109.44M | -$15.76M |
| Capital expenditure | $998,000 | $490,000 |
| Free cash flow | -$110.44M | -$16.25M |
| Investing cash flow | $94.86M | -$17.43M |
| Financing cash flow | -$2.91M | -$155,000 |
| Depreciation & amortization | $1.10M | $859,000 |
| Stock-based compensation | $9.47M | $12.43M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.